skip to content

Matrix Genomics

empowering people through
genetic knowledge

Management Team

Larry S. Corder, PhD, President and CEO of Matrix Genomics, and Scientific Director Elizabeth H. Corder, PhD, share a passion for improving health outcomes through personal genomics.

Larry S. Corder, PhD
President and CEO

Dr. Larry Corder, a professor of Demography at Duke University for two decades, has extensive experience with collecting data and refining and developing products. He fielded a large nationally representative longitudinal survey of elderly Americans to define health in terms of functional capabilities, or activities of daily living. This information has been used to chart the health of older Americans and predict future costs of health care for the country. He has authored or coauthored over 70 peer reviewed publications, many of which relate directly to Matrix Genomics' activities.

Elizabeth H. Corder, PhD
Scientific Director

Dr. Elizabeth Corder is a trained pharmacist, genetic & pharmacoepidemiologist and biostatistician. She was the lead author on the landmark 1993 Science article that identified APOE e4 gene dose effect on Alzheimer's disease (AD), i.e. each additional copy of the E4 allele multiplies risk approximately 3-fold, accounting for at least half of the genetic background for AD. This continues to be the one established genetic risk factor for AD in general populations. Her 1994 Nature Genetics article identified the APOE E2 allele as protective. Her 1995 Neurology article described how APOE polymorphism was not associated strongly with progression of disease among AD patients. Her 1998 Nature Medicine article extended the association of APOE E4 to neurologic symptoms among HIV patients.

Yet, this one gene does not fully describe the risk for AD for individuals. Thus, beginning in1993 Corder began applying grade-of-membership analysis to genetic data to better define risk by incorporating information on multiple genetic factors. This approach efficiently combines information from a number of relevant genes to define a wide range of risk and to provide meaningful risk scores for individuals.